ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Gilead licenses remdesivir production to India and Pakistan

Royalty-free deals allow makers to distribute coronavirus drug to 127 countries

Remdesivir has been granted emergency use authorization to treat COVID-19 by the U.S. Food and Drug Administration.   © Reuters

NEW DELHI -- U.S.-based Gilead Sciences has tied up with India's Cipla and Jubilant Life Sciences, Pakistan's Ferozsons Laboratories and two other generic pharmaceutical makers to ramp up the supply of remdesivir, its closely watched investigational coronavirus drug.

The non-exclusive voluntary licensing agreements allow the partner companies to produce remdesivir for distribution in 127 countries, Gilead said in a statement. "The countries consist of nearly all low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access," the statement says.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more